Senior Director, Development Business Technology
Munther has over 20 years of experience in the pharmaceutical industry. He is currently Sr. Director of Development Business technology at Pfizer, a worldwide pharmaceutical company. Munther is currently the head of Clinical Paradigm within the WRD-BT Development at Pfizer, Munther is spearheading initiatives driving innovation in development operations to align with the paradigm shift in the clinical trials execution model and emerging technologies. Munther Led the Clinical Aggregation Layer (CAL) implementation of a high-profile, large-scale clinical private cloud of clinical and operational data. In addition, he has extensive experience in application and system strategies, best practices, and standards that work for clinical and enterprise architecture, information management, workflow/process automation and integration of both home-grown and commercial applications across mixed platforms.
Dr. Mehdi Benchoufi
Assistant Professor, Clinical Epidemiology Center, Hôtel Dieu Hospital
Blockchain for Clinical Trials Specialist
Mehdi Benchoufi is an Assistant Professor in Epidemiology in Clinical Epidemiology Center, at Hôtel Dieu Hospital, with Pure Mathematics and Computer Science background. His main interests are on the augmentation of healthcare by new technologies, and Open Science as an inclusive tool to improve research processes. He most recently (2017) co-authored a groundbreaking white paper on Blockchain for improving research quality. See the research paper on the NCBI website.
Oskar Buhre has been a founding team member of a number of financial service and consumer application start-ups including; CRYEX (a Swedish institutional grade bitcoin exchange founded in early 2015 and acquired by Safello in late 2017).
In addition, he has 10 years of executive experience in analytical consulting and corporate advisory.
Recognizing the considerable potential of cloud and blockchain technologies in the healthcare industry and the need for better solves for care continuum and pervasive cyber-security issues, Robert founded Embleema in 2017 after a distinguished career at IBM and QuintilesIMS. Robert worked for IBM in Europe and the US for more than 15 years, serving in key technical and management positions such as Global Wireless Solutions Executive in the US and Director of Telecommunications, Media & Utilities Sector for IBM France. In June of 2007, Robert joined IMS Health France and served as the General Manager of the affiliate in 2011. He then moved to Shanghai in China in 2013 to run the Asia Pacific and China operations for IMS Health. Robert was subsequently promoted in 2015 to Senior Vice President, Global Technology Solutions, responsible for the management of a 1,400 employees and $800 million business, delivering SaaS solutions for the healthcare and life sciences industries globally. Robert graduated with a Master’s Degree in Engineering from the Ecole Polytechnique in Paris, France in 1988 and obtained a Master’s in Computer Sciences shortly thereafter from Ecole Nationale Superieure des Telecommunications in 1990
Founder and CEO
Obesity PPM Inc
Heather Flannery is the Founder and Chief Executive Officer of Obesity Prevention, Policy, and Management, Inc. (“Obesity PPM”), an innovative provider of disease management, population health, research administration, and information technology managed services for health systems in the Americas, and an early adopter of distributed ledger technology. Ms. Flannery has driven continuous business model innovation via technology early adoption throughout her 23-year career as an entrepreneur and strategist. She has consulted in the public sector in context of international development, and brings a global health perspective to her initiatives. Ms. Flannery is a broad, lateral thinker who applies complex adaptive systems theory to identify, advance, and course-correct the critical path to progress against very large-scale macroscopic challenges, focusing in the health sector since 2006. Due to her personal life experience, Ms. Flannery is intrinsically motivated to impact population health and economic prosperity through non-communicable disease prevention and treatment. She builds mission-driven organizations aligned by shared values: making measurable societal contributions, creating economically sustainable interventions, and prioritizing diversity and inclusion. Ms. Flannery is also a participant in the Blockchain Working Group at the Health Information and Management Systems Society (HIMSS), the Healthcare Working Group in the Government Blockchain Association, a Founding Member at HL7’s FHIR Foundation, the organizer of the DC Distributed Health Blockchain Innovation Working Group, Advisory Board member for the Institute for Healthcare Financial Technology, and a member of the Board of Directors at the non-profit Virginia Obesity Research Institute.
Mark Graves, Jr.
CEO & Co-Founder
Mark Graves, Jr. is CEO, and co-founder of MyIRE, Inc. A 15+ year veteran of helping facilitate clinical research processes, Graves has spent the last six years of his career developing the first fully-integrated suite of intelligent research tools to accelerate medical and scientific discovery and to facilitate global reproducible research. Graves’ technology solutions have supported medical research conducted by private practice physicians all the way up to large health care systems and medical universities. Graves is an avid speaker on scientific integrity and reproducibility in research, and a consultant on the use of open source and Blockchain technology to enhance research integrity.
Basker Gummadi, MS, PMP, PgMP
Basker Gummadi is a professional with over 22 years of experience and has a strong background in project, program management, technical architecture and business process modelling. He led several merger and acquisition efforts across global R&D organizations and delivered innovative, award winning global projects to realize strategic enterprise business goals.
He is very passionate about innovation and is an innovation coach. He mentored teams in Design Thinking and Systematic Inventive Thinking methodologies to foster innovation.
Basker has a great understanding of technology enablers like Artificial Intelligence, Machine Learning, Block Chain and Big Data. He is researching, collaborating, and exploring the right leverage of such technologies to execute Digital transformations. His current focus is on optimizing Clinical Trial with Block Chain, and providing Real World Evidence based solutions using Big Data.
Donna Houlne, BSN, MHA, MHRM
US Healthcare Leader
Global Business Services, IBM
A senior healthcare executive with more than 30 years of hospital operations and consulting experience. Proven ability to create multi-disciplinary alliances and teams in order to meet the demands of the challenging and fluid healthcare environment. Recognized for being a hands-on, pro-active troubleshooter who can rapidly identify business problems, formulate resolution strategies, initiate change and implement new processes in challenging and diverse environments.
Key strengths include: Ability to develop and manage complex and diverse relationships; Strong project management; highly principled and values driven individual; Resourceful and creative problem-solver;
Donna has worked in or served most segments of the healthcare industry including Provider; not-for-profit, for-profit, academic medical centers; physician office practices healthcare payers, and life science industry.
Senior Manager, Clinical Operations Lead | WIN UK Chapter Co-Lead
Clinical Study Leadership, BIOGEN
An innovation award winning operational strategy expert and patient engagement thought leader with over 17 years in the NHS on commission by the Department of Health and in Industry (Hoffman La-Roche, Amgen, ALMAC, ICON and Biogen). Member of the DIA Patient Engagement Voluntary Community Leadership team and the PHUSE Emerging Technologies working group on adoption of Blockchain technology in the pharmaceutical industry. Currently an R&D Transformational Change Champion.
Experience across various therapeutic areas and phases of trials in drug development include creation and execution of successful strategies for research protocols and CRO oversight, expertise in technologies such as eCOA and IVRS, creation of optimal drug packaging and administration concepts, mapping the patient journey, planning and executing effective global site and patient engagement campaigns using direct to patient methods, leading and coaching remote and complex global teams. Completed an Executive MBA consulting report on ‘Implementing Patient Engagement at a Biotechnology Company.
Dr. Alice Landis-McGrath
IBM Watson Health Oncology
Dr. Alice Landis-McGrath is a member of IBM Watson Health Oncology and Genomics group, focused on the use of cognitive technologies at the point of care. In this role, Alice provides global clinical Subject Matter Expert support for Watson for Oncology, Clinical Trials Matching, and Genomics. Alice joined IBM Watson Health from The Advisory Board Company where she was the Vice President in the Consulting and Management division, leading the Optimization service line. She has 16 years of clinical informatics experience, from electronic medical record implementation and optimization, business process and workflow redesign, clinical governance and adoption, reporting and analytics, to IT strategy. During her career, she has worked with individual ambulatory clinics, small regional medical centers, large academic institutions, and integrated delivery networks. Alice received her MD from the University of Pennsylvania School of Medicine, and her BA in Chemistry from Franklin & Marshall College.
Dr. Rhea Mehta
Dr. Rhea Mehta, Bowhead Health CEO, has a PhD in molecular toxicology and nutritional biochemistry and is a certified integrative health coach. Rhea has over 10 years of experience in health-related research and practice, and as a wellness community builder.
Dr. Michelle Longmire
Dr. Longmire is a physician and entrepreneur driven to improve human health through advances in technology. Dr. Longmire founded Medable in 2014 to enable healthcare technology to be as seamless, integrated, and adaptive as the human body. Medable is transforming healthcare by enabling patient generated data to drive healthcare delivery, clinical research, and personalized and predictive medicine.
Professor, New York Law School
Co-Director, The Accord Project
Houman Shadab is a prolific and influential expert in law, business, and technology, Houman is a professor at New York Law School and cofounder of Clause.io as well as a director of the open source legal technology consortium, the Accord Project. His areas of focus are legaltech and fintech, startups, supply chains and professional services, and blockchain. Houman has testified before the federal government several times, is widely published and cited, and also often advises a wide variety of companies.
Dr. Vahan Simonyan
Lead Scientist, HIVE
R&D Director of Bioinformatics, FDA
Adjunct Professor, George Washington University
In 2017, the technology experts Dr. Simonyan (FDA) and Shahram Ebadollahi (IBM) have led a research collaboration between FDA and IBM on testing feasibility of blockchain for healthcare data. The initiative called Healthcare Data Exchange Framework (HDEF) targets the facilitation of healthcare data transactions by creating an incentive framework for patient ownership of their medical data.
Dr. Simonyan has a solid scientific background in varied academic disciplines: MS in Physical Organic Chemistry, Ph.D. in Quantum Physics and Mathematics, post-doctoral training in Nanotechnology and Quantum Statistical Thermodynamics. After 2001, he switched his expertise to biotechnology and biomedical informatics and currently serves at the FDA as a lead scientist of HIVE, R&D Director of Bioinformatics. Vahan is a prolific author of scientific publications in physics, chemistry, quantum chemistry, nanotechnology, biotechnology, population dynamics, and bioinformatics.
Additionally, Dr. Simonyan is an adjunct professor at the George Washington University, where he teaches and develops curriculums for biomedical big data informatics and biostatistics research and development courses.
In 2013, High-performance Integrated Virtual Environment (HIVE) codebase was donated by Dr. Simonyan to the US government in order to build a platform ready to accept NGS data at the US FDA for regulatory review. Today HIVE has supported regulatory review and research leading to peer-reviewed publications in genetics, genomics, proteomics, data modeling, and bioinformatics.
In 2016, Dr. Simonyan and his colleagues (Raja Mazumder and Jeremy Goecks) have published the first BioCompute paper where they introduced the new concept for bioinformatics harmonization. Today BioCompute is represented by a large international consortium of regulatory and research scientists from academia, industry, technology companies and government organizations.
Associate Partner, Healthcare and Life Sciences, Blockchain
Bio coming soon...
Founder & CEO
Himanshu has 25+ years of work experience across life sciences and financial institutions. In his last role, as business leader for an IT major, he was responsible for businesses upwards of $400 million across life science and technology customers. He is also trained as a CPA.